Please use this identifier to cite or link to this item:
Title: Combination therapy using inhalable GapmeR and recombinant ACE2 for COVID-19
Authors: Verma, Navin Kumar
Fazil, Mobashar Hussain Urf Turabe
Duggan, Shane P.
Kelleher, Dermot
Keywords: Science::Medicine
Issue Date: 2020
Source: Verma, N. K., Fazil, M. H. U. T., Duggan, S. P., & Kelleher, D. (2020). Combination therapy using inhalable GapmeR and recombinant ACE2 for COVID-19. Frontiers in Molecular Biosciences, 7, 197-. doi:10.3389/fmolb.2020.00197
Project: MOE2017-T2-2-004
Journal: Frontiers in Molecular Biosciences
Abstract: Here we report our perspective on applying GapmeR technology in combination with recombinant angiotensin-converting enzyme 2 (ACE2) in the treatment of COVID-19 patients. GapmeR is a cell-permeating antisense single-stranded DNA molecule that can be designed to specifically target intracellular severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Once internalized into host cells, such as lung alveolar cells, GapmeR molecules can bind to the viral RNA. This RNA/DNA hybrid will then be degraded by the RNase H enzyme abundantly present in the host cells. GapmeRs can be delivered to COVID-19 patients through inhalation or via nebulization. SARS-CoV-2-targeted GapmeR can also be given to frontline healthcare workers as a prophylactic protection. The recombinant ACE2 protein, the efficacy of which is being evaluated in clinical trials, will bind to the spike (S) glycoprotein of extracellular SARS-CoV-2 and potentially block viral infectivity. We propose that combining inhalable SARS-CoV-2-targeted GapmeRs with recombinant ACE2 could provide a viable and rapidly implementable more effective therapeutic approach for eradicating SARS-CoV-2 and save millions of lives.
ISSN: 2296-889X
DOI: 10.3389/fmolb.2020.00197
Rights: © 2020 Verma, Fazil, Duggan and Kelleher. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:LKCMedicine Journal Articles

Files in This Item:
File Description SizeFormat 
fmolb-07-00197.pdf1.46 MBAdobe PDFView/Open

Citations 50

Updated on Mar 10, 2021

Citations 50

Updated on Mar 8, 2021

Page view(s)

Updated on May 21, 2022


Updated on May 21, 2022

Google ScholarTM




Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.